Drug Trial Radar · NCT05907122
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
256
Actual
Start
Jul 26, 2023
Primary completion
Mar 26, 2025
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.
Conditions
- Melanoma
Interventions
ABP 206Drug
ABP 206 will be given intravenously over a period of 30 minutes, every 4 weeks (Q4W) for a total of 12 months.
FDA-licensed NivolumabDrug
FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
EU-authorized NivolumabDrug
FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Serum Concentration-time Curve from Time Zero to 28 Days (AUC0-28d)Time frame: Day 1 (Postdose) through Day 28
- Area Under the Serum Concentration-time Curve Over the Dosing Interval at Steady State (AUCtau_SS)Time frame: Week 17 through Week 21
Locations
76 sites in 22 countries. Site status is shown where the registry gives one.
Cancer and Blood Specialty clinic
Long Beach, California
St. Vincent Frontier Cancer Center - Oncology
Billings, Montana
Centro De Investigaciones Medicas Mar Del Plata (CIMMDP) - Rheumatology
Mar Del Plata, Río Negro Province, Argentina
University Clinical Hospital Mostar - Clinic for Lung Diseases
Mostar, Bosnia and Herzegovina
Clinical Center University of Sarajevo - Clinic of Oncology
Sarajevo, Kanton Sarajevo, Bosnia and Herzegovina
University Clinical Centre of the Republic of Srpska - Gastroenterology
Banja Luka, Republika Srpska, Bosnia and Herzegovina
University Clinical Center Tuzla - Oncology, Hematology and Radio
Tuzla, Tuzlanski Kanton, Bosnia and Herzegovina
Cantonal hospital Zenica - Oncology
Zenica, Zeničko-dobojski Kanton, Bosnia and Herzegovina
Faculdade de Medicina de Sao Jose do Rio Preto-SP (FAMERP) - Hospital de Base (HB) - Oncology
São Paulo, Brazil
ATO Oncologia
Fortaleza, Ceará, Brazil
Hospital Sao Rafael
Salvador, Estado de Bahia, Brazil
Hospital Sirio Libanes - Brasilia - Oncology
Brasília, Federal District, Brazil
Cto Centro de Tratamento Oncologico Ltda
Belém, Pará, Brazil
Instituto de Oncologia do Parana
Curitiba, Paraná, Brazil
PUCRS - Hospital Sao Lucas - Uniao Brasileira de Educacao e Assistence
Porto Alegre, Rio Grande do Sul, Brazil
CEPON - Centro de Pesquisas Oncológicas
Florianópolis, Santa Catarina, Brazil
Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor
Barretos, São Paulo, Brazil
Oncocentro Apys
Valparaíso, Valparaiso, Chile
Klinicki bolnicki centar "Sestre milosrdnice" - Pediatrics
Grad Zagreb, City of Zagreb, Croatia
University Hospital Centre Zagreb - Oncology department
Zagreb, City of Zagreb, Croatia
LTD "Israel-Georgian Medical Research Clinic Healthycore"
Tbilisi, Georgia
JSC "K.Eristavi National Center of Experimental and Clinical Surgery"
Tbilisi, Georgia
Azienda Ospedaliera Universitaria Federico II
Naples, Italy
Istituto Dermopatico dell'Immacolata (IDI) - IRCCS - Oncologia
Roma, Italy
Policlinico Santa Maria alle Scotte, Azienda Ospedaliero Universitaria Senese - Immunoterapia Oncolo
Siena, Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.R.L
Meldola, Forli, Italy
Kumamoto University Hospital - Dermatology
Kumamoto, Japan
Niigata Cancer Center Hospital - Dermatology
Niigata, Japan
Nagoya City University Hospital - Dermatology
Nagoya, Aiti [Aichi], Japan
Sapporo Medical University Hospital
Sapporo, Hokkaidô [Hokkaido], Japan
National Hospital Organization Kagoshima Medical Center - Haematology
Kagoshima, Kagosima [Kagoshima], Japan
Osaka International Cancer Institute - Dermatological Oncology
Osaka, Ôsaka [Osaka], Japan
Shizuoka Cancer Center - Dermatology
Kōtoku, Tôkyô [Tokyo], Japan
Keio University Hospital - Dermatology
Shinjuku-ku, Tôkyô [Tokyo], Japan
National Cancer Institute - Conservative Tumour Therapy
Vilnius, Vilnius County, Lithuania
Hospital Pulau Pinang - Rheumatology
Pulau Pinang, Pahang, Malaysia
Hospital Umum Sarawak
Kuching, Sarawak, Malaysia
National Cancer Institute - Radiotherapy and Oncology
Putrajaya, Selangor, Malaysia
Hospital Universiti Sains Malaysia
Kubang Kerian, Terengganu, Malaysia
Hospital Kuala Lumpur - Surgery
Kuala Lumpur, Wilayah Persekutuan Kuala Lump, Malaysia
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.